Evidence map›Paper›PMID 38005332›Full record

ArticleMolecules (Basel, Switzerland)2023

Bioactive Peptides from

Zonghui Sun, Weixia Wang, Jinli Liu, Shengcan Zou, Dongli Yin, Chenghan Lyu, Jia Yu, Yuxi Wei

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Zonghui SunCollege of Life Sciences, Qingdao University, Qingdao 266071, China.
Weixia WangQingdao Chenlan Pharmaceutical Co., Ltd., Qingdao 266061, China.
Jinli LiuQingdao Chenlan Pharmaceutical Co., Ltd., Qingdao 266061, China.
Shengcan ZouQingdao Chenlan Pharmaceutical Co., Ltd., Qingdao 266061, China.
Dongli YinQingdao Chenlan Pharmaceutical Co., Ltd., Qingdao 266061, China.
Chenghan LyuQingdao Chenlan Pharmaceutical Co., Ltd., Qingdao 266061, China.
Jia YuCollege of Life Sciences, Qingdao University, Qingdao 266071, China.ORCID 0000-0002-8366-2960
Yuxi WeiCollege of Life Sciences, Qingdao University, Qingdao 266071, China.ORCID 0000-0002-0616-479X
Qingdao University · CN

Funding

Qingdao key technology research and industrialization demonstration projects No. 22-3-3-hygg-5-hy
6 · The paper itself

Abstract

Hypertension is a common disease that affects human health and can lead to damage to the heart, kidneys, and other important organs. In this study, we investigated the regulatory effects of bioactive peptides derived from

Indexed as

DesoxycorticosteroneHypertensionAcetatesAnimalsAntihypertensive AgentsBlood PressureHumansPeptidesRatsRats, Inbred SHRAcetatesAntihypertensive AgentsDesoxycorticosteronePeptidesantihypertensioncardiorenal protectionDOCA–salt hypertensive ratsgut microbiotaoxidative stressRuditapes philippinarum peptides

Identifiers

PMID38005332
PMCPMC10675683
OpenAlexW4388733509

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.